Explore our core validated services: from origin-specific potency screening to toxicology validation and finished pharmaceutical dosage OEM supply.
In the contemporary global landscape of botanical therapeutics, nutraceutical manufacturing, and phytopharmaceutical development, the paradigm of Maximum Safety has shifted from a passive compliance checkpoint to an active, multidimensional technological benchmark. Historically, natural products operated under the presumption of safety derived merely from long traditional usage. However, evolving regulatory frameworks—including the US FDA Botanical Drug Guidance, the European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) monographs, and China's NMPA Class 1/Class 2 Traditional Chinese Medicine (TCM) modern registration pathways—demand quantifiable, reproducible, and verifiable scientific dossiers before products enter human trials or retail distribution.
As an established biopharmaceutical research organization and contract development and manufacturing enterprise based in Changsha, Hunan, MedGence (Yineng Pharma) formalizes "OEM Maximum Safety" across four mandatory pillars:
MedGence leverages over 14 years of rigorous biopharmaceutical CRO/CDMO expertise, having served more than 100 enterprise pharmaceutical manufacturers and Class 3A clinical hospitals. With an R&D core of 300+ scientists and researchers, our institution has executed modern medical studies across 83 classic TCM formulas, developed 22 innovative natural medicines, achieved 56 hospital preparation registrations, and engineered precision quality standards for nearly 400 single-herb raw materials.
Analyzing procurement vulnerabilities, international regulatory hurdles, and why leading brand owners are shifting to certified safety-first CDMO architectures.
In North America, FDA 21 CFR Part 111 (Dietary Supplements) and Part 210/211 (cGMP for Pharmaceuticals) are enforcing uncompromising safety dossiers. Under the Foreign Supplier Verification Program (FSVP), importers are personally liable for botanical adulteration and undisclosed excipients. Simultaneously, the European Food Safety Authority (EFSA) and EMA demand comprehensive botanical characterization dossiers before approving Novel Food or Traditional Herbal Medicinal Product (THMPD) registrations.
Global raw material supply chains face compounding challenges: environmental degradation, uncontrolled pesticide usage in unregulated harvesting hubs, and severe batch-to-batch variability caused by shifting meteorological phenomena. Without an upstream CRO partner capable of seasonal potency mapping and multi-origin toxicological assaying, global manufacturers risk devastating product recalls, reputational collapse, and multimillion-dollar regulatory fines.
Multinational pharmaceutical corporations, clinical institutions, and direct-to-consumer dietary giants have discontinued the fractured procurement model—where discovery is contracted to a Western lab, crude extraction to a commodity trader, and formulation to a packaging shop. Modern efficiency demands single-entity accountability where preclinical data, validated analytical testing, pilot extraction, and commercial OEM batch production coexist seamlessly under audited non-disclosure governance.
How state-of-the-art Chinese biopharmaceutical facilities achieve unprecedented economies of scale, chemical purity, and delivery speed without compromising safety.
MedGence’s manufacturing hubs integrate automated supercritical CO2 extraction, continuous countercurrent extraction lines, and ceramic nanofiltration membranes. This avoids the high thermal degradation of fragile active molecules while eliminating volatile toxic organic solvents.
By leveraging industrial-scale simulated moving bed (SMB) chromatography and macroporous adsorption resin columns, our production lines isolate single active botanical monomers (98%+ purity) at one-third the unit cost of Western batch chromatography systems.
Located in Hunan—the geographic heart of China’s richest medicinal plant biodiversity—our facility maintains direct geo-authentic (Daodi) sourcing contracts. Raw materials are harvested at optimal physiological phenology windows, tracked by GPS origin certification.
China’s unmatched industrial infrastructure, domestic equipment manufacturing ecosystem, and highly concentrated pool of bioprocess engineers empower MedGence to deliver full preclinical toxicology and multi-ton commercial OEM shipments at 35–55% lower total expenditure.
From primary discovery and harvest window optimization to in vivo toxicology and finished dosage cGMP production.
Plants synthesize vast arrays of alkaloids, polysaccharides, saponins, and flavonoids. Using our proprietary phytochemical database of hundreds of thousands of research batches, we systematically identify the chemical entities delivering target bioactivity while filtering out inherent cytotoxic metabolites.
Review Screening ProtocolsThe concentration of secondary metabolites varies drastically depending on geographical origin (Daodi terroir), climate seasonality, and anatomical plant parts (root, rhizome, aerial leaf, fruit). We quantify these variables to lock down an optimal, high-potency, cost-efficient, and sustainable sourcing strategy.
Inspect Origin Potency DataA validated, stability-indicating test method is the absolute foundation of maximum safety. We establish standardized identification and quantification protocols using HPTLC, HPLC-DAD, GC-FID, and chromatographic fingerprinting to verify identity and eradicate batch drift.
Examine Method ProtocolsOnce candidate molecules are established, industrial economics dictate feasibility. We optimize raw-material comminution, solid-liquid extraction kinetics, resin adsorption isotherms, vacuum concentration, and spray/freeze drying parameters to maximize purity and industrial safety.
Explore Active ProcessesTransitioning pure botanical extracts into consumer-ready delivery formats often causes oxidation, active ingredient precipitation, hygroscopic clumping, or degradation. Our formulation scientists optimize excipient compatibility, moisture barriers, and dissolution stability.
View Formulation StudiesToxicological evidence is non-negotiable. Our GLP-compliant testing facilities perform acute oral median lethal dose (LD50), 14-day dose-range finding, 90-day sub-chronic repeated oral toxicity, Ames genotoxicity, and in vivo bone marrow micronucleus tests.
Request Toxicology DossiersRapid, high-fidelity cellular screening models map mechanism of action, receptor binding affinity, enzymatic inhibition (e.g., alpha-glucosidase, COX-2, 5-LOX), and free-radical clearance at a fraction of in vivo costs—serving as an indispensable go/no-go developmental gate.
Explore In Vitro AssaysEmpirical efficacy and safety validated across murine, rat, and rabbit disease models. Critical for supporting health claims for functional food authorizations, medical foods, and preclinical exploratory files for botanical Investigational New Drug (IND) applications.
Review In Vivo ModelsFrom randomized, double-blind, placebo-controlled pilot efficacy trials (30–60 human subjects) for premium dietary brands to full GCP-compliant Phase I dose-escalation, Phase II proof-of-concept, and Phase III confirmatory trials for botanical new drug applications (NDAs).
Review Clinical CapabilitiesIntegrating centuries of verified classical TCM synergistic theory with modern bio-enhancers, microencapsulation, and liposomal delivery systems to enhance bioavailability, mitigate bitter botanical astringency, and prevent chemical incompatibility between co-extracted actives.
Explore Formulation IPPilot-to-commercial cGMP extraction of active ingredients supplied as concentrated sterile liquids, standardized spray-dried powders, vacuum-dried pastes, or volatile essential oils. Every drum is accompanied by a comprehensive Certificate of Analysis (COA) and safety audit trail.
Request Active SpecsHigh-speed packaging and formulation across oral liquids, two-piece hard gelatin/HPMC capsules, vegetarian softgels, micro-tablets, effervescent granules, and direct-dissolve stick packs—safeguarded under stringent international mutual non-disclosure covenants.
Request Dosage CatalogA transparent, stage-gated research and manufacturing trajectory designed for procurement officers, regulatory heads, and scientific teams.
Phytochemical library screening, seasonal harvest window determination, origin potency comparison, and initial safety profiling of crude botanical matrices.
Deliverable: Target & Sourcing DossierDevelopment and ICH Q2(R1) validation of HPLC/HPTLC/GC-MS assays, standard curve calibration, reference standard characterization, and chromatographic fingerprints.
Deliverable: Validated QC & QA MonographDesign of Experiments (DoE) modeling for solid-liquid ratio, temperature kinetics, solvent recovery systems, and pilot crystallization or spray-drying parameters.
Deliverable: Key Process Parameters (KPP)Execution of GLP acute oral LD50, 90-day repeated sub-chronic rodent studies, Ames mutagenicity, and in vitro cellular toxicity to establish human safety thresholds.
Deliverable: Certified Toxicology DossierIRB-approved pilot human clinical trials (for functional food claim substantiation) or Phase I–IV clinical investigations required for botanical pharmaceutical registration.
Deliverable: GCP Clinical Study Report (CSR)Bulk production of active pharmaceutical ingredients (APIs) or high-speed manufacturing of retail-ready finished dosage forms under strict confidentiality.
Deliverable: Commercial Batches & COACustomizing extraction purities, bioavailability enhancements, and dosage delivery across primary global health industries.
Standardized plant extracts with proven molecular assays. Designed specifically for Amazon, iHerb, and international specialty retail distribution where heavy metal, pesticide, and solvent non-detectability is essential for brand survival. Supported by small-group human clinical substantiation reports.
High-purity botanical monomers (ginsenosides, artemisinin derivatives, berberine alkaloids, tanshinones, astragalosides) developed as primary active pharmaceutical ingredients (APIs). Supported by full IND-enabling chemistry, manufacturing, and controls (CMC) packages.
Skin barrier repair, melanin suppression (tyrosinase inhibition), and anti-photoaging botanical fractions. Tested against human skin fibroblast cellular models (in vitro) and patch-tested for dermal irritancy to fulfill clean-label, cruelty-free, and EU Cosmetic Regulation requirements.
Our pilot plants and large-scale industrial extraction facilities supply bulk botanical substances across all physical rheologies:
Turnkey contract manufacturing supporting rapid retail readiness, private label packaging, and commercial shelf stability:
Fourteen years of rigorous scientific delivery for China’s leading pharmaceutical groups, Class 3A university hospitals, and international innovators.
Our research standards and contract manufacturing protocols support China's most revered biopharmaceutical conglomerates and clinical institutions.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Pharma Group
Dihon Pharma
Golden Throat Group
Yangtze River Pharma
Beihai Gofar Bio
Humanwell Healthcare
SCIMYTH Pharma
Shandong Hanfang
Luoxin Pharma
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharma
Heng Chang Pharma
Baotou TCM
Kamp Medicine
Guangxi Santo
Kangshou Pharma
Juwang Pharma
Beijing Tcmages
Guizhou Ruihe
CR Jinchan Pharma
Kangmei Pharma
Tianjicaotang
Kingstone Unite
Shuguang Hospital (Shanghai)
Hunan Affiliated TCM Hosp.
1st Hosp. Hunan Univ. TCM
2nd Xiangya Hosp. CSU
2nd Hosp. Hunan Univ. TCM
Orthopedics TCM Zhuzhou
Comprehensive technical answers to critical questions raised by VP of R&D, Chief Scientific Officers, and Global Supply Chain Directors.
Connect directly with our senior research team to evaluate specifications, request analytical validation packages, or initiate pilot batch production.
Whether you require targeted LD50 rodent safety dossiers for a regulatory submission, analytical method development (HPLC/GC-MS) for patent filings, or multi-ton cGMP contract manufacturing of finished dosage forms, MedGence offers direct scientific consultation under strict non-disclosure.
